Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

Marc P. Bonaca,Patrice Nault,Robert P. Giugliano,Anthony C Keech,Armando Lira Pineda,Estella Kanevsky,Julia Kuder,Sabina A. Murphy,J. Wouter Jukema,Basil S. Lewis,Lale Tokgözoğlu,Ransi Somaratne,Peter S. Sever,Terje R. Pedersen,Marc S. Sabatine

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

2018

Marc P. Bonaca
Patrice Nault
Robert P. Giugliano
Anthony C Keech
Armando Lira Pineda
Estella Kanevsky
Julia Kuder
Sabina A. Murphy
J. Wouter Jukema
Basil S. Lewis
Lale Tokgözoğlu
Ransi Somaratne
Peter S. Sever
Terje R. Pedersen
Marc S. Sabatine

Background:The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiov...

Keywords:

Proprotein convertase
Internal medicine
Cardiology
PCSK9
Cholesterol
Evolocumab
Low-density lipoprotein
Kexin
Lipoprotein
Medicine
Intermittent claudication

Correction
Cite
Save
Machine Reading By IdeaReader

References

Citations